Bristol-Myers Squibb Company ((BMY)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Bristol-Myers Squibb Company is currently conducting a Phase 3 clinical study titled ‘A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)’. The study aims to assess the effectiveness of KarXT in treating manic episodes in individuals with Bipolar-I Disorder, a significant mental health condition.
The intervention being tested is KarXT, a drug designed to manage symptoms of mania in Bipolar-I Disorder. It is compared against a placebo to determine its efficacy and safety over a three-week inpatient period.
The study employs a randomized, double-blind, placebo-controlled design with a parallel intervention model. Both participants and investigators are masked to ensure unbiased results, and the primary purpose is treatment-focused.
The study began on June 13, 2025, with an expected completion within seven weeks, including screening and follow-up. The latest update was submitted on August 11, 2025, indicating ongoing recruitment.
This study could significantly impact Bristol-Myers Squibb’s market position by potentially introducing a new treatment option for Bipolar-I Disorder, which may positively influence their stock performance. Investors should watch for updates, as successful results could enhance competitiveness in the pharmaceutical industry.
The study is currently ongoing, with further details available on the ClinicalTrials portal.